Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.84 Insider Own6.11% Shs Outstand3.81M Perf Week5.75%
Market Cap1.47M Forward P/E- EPS next Y-1.29 Insider Trans0.00% Shs Float3.57M Perf Month-3.50%
Income-7.54M PEG- EPS next Q-0.32 Inst Own18.16% Short Float / Ratio0.36% / 0.07 Perf Quarter-51.75%
Sales0.00M P/S- EPS this Y75.31% Inst Trans16.69% Short Interest0.01M Perf Half Y-91.13%
Book/sh3.86 P/B0.10 EPS next Y50.95% ROA-39.14% Target Price1.00 Perf Year-91.58%
Cash/sh3.02 P/C0.13 EPS next 5Y20.00% ROE-48.29% 52W Range0.26 - 14.18 Perf YTD-94.85%
Dividend- P/FCF- EPS past 5Y6.23% ROI-48.75% 52W High-97.28% Beta0.87
Dividend %- Quick Ratio3.59 Sales past 5Y-2.43% Gross Margin- 52W Low48.46% ATR0.05
Employees20 Current Ratio6.79 Sales Q/Q- Oper. Margin0.00% RSI (14)49.33 Volatility10.31% 12.88%
OptionableNo Debt/Eq0.00 EPS Q/Q92.60% Profit Margin- Rel Volume0.33 Prev Close0.39
ShortableYes LT Debt/Eq0.00 EarningsJun 01 BMO Payout- Avg Volume178.70K Price0.39
Recom1.00 SMA202.22% SMA50-7.92% SMA200-86.73% Volume59,350 Change-1.00%
Date Action Analyst Rating Change Price Target Change
May-22-20Downgrade B. Riley FBR Buy → Neutral $11 → $8
Feb-04-20Initiated Craig Hallum Buy $18
Jan-30-20Resumed Cantor Fitzgerald Overweight $9 → $14
Dec-02-19Initiated Canaccord Genuity Buy
Dec-12-18Initiated B. Riley FBR Buy $28
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
Nov-21-23 07:32AM
Nov-20-23 04:32PM
Sep-26-23 08:30AM
Sep-22-23 04:05PM
Aug-10-23 11:08AM
09:20AM Loading…
Jul-14-23 09:20AM
Jul-10-23 08:00AM
Jun-01-23 08:05AM
May-09-23 07:00AM
May-04-23 04:00PM
Mar-29-23 05:00PM
Feb-08-23 08:00AM
Jan-06-23 06:34AM
Jan-04-23 08:00AM
05:00PM Loading…
Dec-14-22 05:00PM
Sep-14-22 12:00PM
Aug-04-22 08:00AM
Jul-18-22 11:43AM
Jul-13-22 10:53AM
Jul-07-22 10:18AM
Jun-17-22 04:15PM
Jun-15-22 10:47AM
May-17-22 08:00AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-26-22 08:30AM
Mar-29-22 10:18AM
07:30AM Loading…
Jan-11-22 07:30AM
Jan-10-22 07:30AM
Nov-08-21 07:30AM
Nov-01-21 12:38PM
Oct-11-21 08:00AM
Aug-24-21 12:03PM
Aug-19-21 11:49AM
Aug-16-21 08:00AM
Aug-11-21 12:48PM
Aug-10-21 03:41PM
Aug-05-21 07:00AM
Aug-03-21 04:49AM
Aug-02-21 09:26AM
Jul-29-21 08:30AM
Jun-04-21 06:57AM
May-13-21 07:50AM
May-06-21 08:30AM
May-03-21 08:30AM
Mar-19-21 07:23AM
Mar-18-21 07:00AM
Mar-16-21 08:00AM
Mar-11-21 08:30AM
Feb-16-21 09:29AM
Feb-11-21 11:16AM
Feb-04-21 01:30AM
Jan-26-21 08:00AM
Jan-19-21 08:00AM
Dec-17-20 07:00AM
Dec-04-20 09:08AM
Nov-12-20 07:00AM
Nov-10-20 08:40AM
Nov-09-20 08:00AM
Nov-05-20 08:30AM
Oct-20-20 08:31AM
Sep-10-20 08:49AM
Aug-06-20 07:00AM
Jul-30-20 08:30AM
Jul-22-20 10:34AM
Jul-14-20 05:31PM
Jul-06-20 07:55AM
Jun-26-20 06:42AM
Jun-10-20 08:34AM
May-14-20 05:31PM
May-07-20 08:30AM
May-02-20 09:36AM
Mar-26-20 09:40PM
Mar-12-20 07:00AM
Mar-05-20 08:30AM
Feb-28-20 09:30AM
Feb-05-20 04:11PM
Jan-03-20 08:25AM
Dec-14-19 07:21PM
Dec-04-19 09:26AM
Nov-29-19 08:41AM
Nov-08-19 10:57PM
Nov-06-19 07:00AM
Nov-04-19 09:10AM
Oct-31-19 08:30AM
Oct-30-19 08:30AM
Sep-26-19 08:00AM
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.